ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. lowered their price target on shares of ORIC Pharmaceuticals from $19.00 […]

Related Keywords

United States ,China , ,Citigroup ,China Universal Asset Management Co ,Pharmaceuticals Daily ,Cantor Fitzgerald ,Pharmaceuticals Price Performance ,Sherbrooke Park Advisers ,Jpmorgan Chase Co ,Algert Global ,Pharmaceuticals Inc ,Free Report ,Get Free Report ,Universal Asset Management ,Park Advisers ,